Citations

Clear

116 citation(s) found for "Colby, Thomas".

Interobserver Agreement in Hepatitis C Grading and Staging and in the Banff Grading Schema for Acute Cellular Rejection: The “Hepatitis C 3” Multi-Institutional Trial Experience
Watkins, David L., Williams, James W., Colby, Thomas V. , Sharkey, Francis E. , Corless, Christopher L. , Lewin, David , Petrovic, Lydia, Kanel, Gary C., Theise, Neil D. , West, A. Brian, Koehler, Alison, Jhala, Nirag, Lefkowitch, Jay H., Lezzoni, Julia, Jennings, Linda W. , Tillery, G. Weldon, Klintmalm, Göran B. , Netto, George J. , Petris, Giovanni De , Sharma, Shobha

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 8 | Pages: 1157-1162

10.5858/2006-130-1157-iaihcg | PMID 16886238 Get It

Abstract Context. —Establishing adequate interobserver agreement is crucial not only for standardization of patient care but also to ensure validity of findings in multi-institutional trials. Objective. —To evaluate interobserver agreement in assessing chronic hepatitis C (HCV) and acute cellular rejection (ACR) among 17 hepatopathologists involved in the “Hepatitis C 3” trial. Design. —The trial is a randomized multicenter (17 institutions) study involving 312 patients undergoing transplantation for HCV. Patients are randomized to 3 treatment arms. For final data analysis, all biopsy specimens are reviewed by a central pathologist (G.J.N.). Recurrence of HCV is evaluated according to the Batts and Ludwig schema. The 1997 Banff schema is used to evaluate ACR. To assess interobserver agreement, hematoxylin-eosin–stained sections from 11 liver biopsy specimens (6 HCV and 5 ACR) were sent by the central pathologist to 16 local pathologists from 13 institutions. Statistical analysis was performed on raw ACR/HCV data as well as data grouped according to clinically significant primary endpoint cutoffs. Results. —Statistically significant agreement was found among all participating pathologists ( P < .001). On κ analysis, the degree of agreement was rated “moderate” for HCV grade and stage and ACR global grading (κ = 0.30, 0.33, and 0.37, respectively). Interobserver agreement was weaker for rejection activity index scoring of ACR (κ = 0.15). A stronger degree of agreement was found when scores were grouped based on endpoint cutoffs (κ = 0.76 “almost perfect” for HCV and 0.62 “substantial” for ACR). Conclusions. —An overall statistically significant interobserver agreement was found among 17 pathologists using the 1997 Banff schema and the Batts and Ludwig schema.
A 75-Year-Old Man With an Asymptomatic Pleural-Based Mass Discovered on Routine Chest Radiographs
Qing, Gefei , Colby, Thomas V. , Leslie, Kevin O., Ionescu, Diana N.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 130 | Issue: 4 | Pages: e62-e65

10.5858/2006-130-e62-aymwaa | PMID 16594763 Get It

Pulmonary Crystal-Storing Histiocytoma
Pierson, Diane M., Qing, Gefei , Li, Maomi, Colby, Thomas V. , Leslie, Kevin O., Ionescu, Diana N.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 10, 2021 | Volume: 129 | Issue: 9 | Pages: 1159-1163

10.5858/2005-129-1159-pch | PMID 16119991 Get It

Abstract We describe the case of a 50-year-old woman with a lung tumor composed of crystal-storing histiocytes. These cells and associated plasma cells failed to show clonal light chain restriction, and the patient had no associated hematologic disorder. The differential diagnosis included crystal-storing histiocytosis, characterized by accumulation of crystallized immunoglobulins, a rare manifestation of monoclonal gammopathies/plasma cell dyscrasias. Crystal-laden histiocytes have previously been described in many organs. Four reports have described crystal-storing histiocytosis in the lung, always associated with a lymphoproliferative disorder. The present patient, 1 other case from our archive, and 1 case reported in the literature, all without an association with lymphoproliferative disorder, make a full description and definition of this lesion appropriate. The morphology, immunohistochemical profile, and electron microscopic features are described herein, and the term pulmonary crystal-storing histiocytoma is proposed. A practical algorithm is presented for the assessment of solitary lung masses composed of large histiocytic cells.
Pulmonary Sclerosing Hemangioma With Lymph Node Metastases
Miyagawa‐Hayashino, Aya , Tazelaar, Henry D. , Langel, Desiree J., Colby, Thomas V. , Tazelaar, Henry D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 29, 2021 | Volume: 127 | Issue: 3 | Pages: 321-325

10.5858/2003-127-0321-pshwln | PMID 12653576 Get It

Abstract Context.—Sclerosing hemangioma is an unusual pulmonary tumor. Previously, 4 patients with pulmonary sclerosing hemangioma and lymph node metastases have been described in the literature. Objective.—To report 4 additional cases of metastatic sclerosing hemangioma. Design.—Retrospective review of the authors' consultation files and review of histologic sections of pulmonary tumors and lymph node metastases. Results.—Four cases of a morphologically benign pulmonary sclerosing hemangioma with regional lymph node metastases (including hilar, peribronchial, and interlobar metastases) were identified. The patients (3 female, 1 male) had a mean age of 39 years (range, 10–56 years). The tumors ranged in size (greatest dimension) from 1.5 to 4.7 cm (mean, 3.1 cm). The pulmonary tumors were typical circumscribed sclerosing hemangiomas without mitotic activity, angiolymphatic invasion, or necrosis. One tumor had focal cytologic atypia. The metastases were identified in hilar lymph nodes that were removed at operation for the lung nodule. One patient received adjuvant chemotherapy for adenocarcinoma. All of the patients are alive. No recurrences or residual disease has been detected at a mean follow-up of 4.7 years (range, 2.3–10 years). Conclusions.—On the basis of case data from the 4 patients described here and the 4 patients described previously, metastases to regional lymph nodes from pulmonary sclerosing hemangioma may occur but are rare and do not appear to affect prognosis.
Hantavirus Pulmonary Syndrome Is Distinguishable From Acute Interstitial Pneumonia
Colby, Thomas V. , Zaki, Sherif R., Feddersen, Richard M. , Nolte, Kurt B.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 28, 2021 | Volume: 124 | Issue: 10 | Pages: 1463-1466

10.5858/2000-124-1463-hpsidf | PMID 11035576 Get It

Abstract Context. —Hantavirus pulmonary syndrome (HPS) and acute interstitial pneumonia (AIP) can share similar clinical presentations. AIP is an acute, diffuse lung disease that has some clinical features suggesting a viral infection, although causative agent(s) have not been identified. Objective. —To clinically, histologically, and immunohistochemically compare cases of HPS to cases of AIP and to determine if any cases of AIP were actually examples of HPS. Design. —Seven cases of HPS and 9 cases of AIP were compared clinically and histologically by semiquantitative grading of features in lung tissue. The cases were also evaluated immunohistochemically for the presence of hantaviral antigens. Results. —Hantavirus pulmonary syndrome had a shorter clinical duration and more acute changes histopathologically; AIP was of longer clinical duration and was usually accompanied by histologic evidence of organization. Hantavirus pulmonary syndrome was distinguished by the presence of immature leukocytes in the pulmonary vasculature. No hantaviral antigens were identified immunohistochemically in the 9 case of AIP. Hantaviral antigens were identified in all 7 cases of HPS. Conclusion. —Cases of AIP and fatal cases of HPS can generally be distinguished on clinical and histologic grounds, and this distinction can be further confirmed immunohistochemically.
Masson Trichrome and Sulfated Alcian Blue Stains Distinguish Light Chain Deposition Disease From Amyloidosis in the Lung
Kunnath-Velayudhan, Shajo, Larsen, Brandon T. , Coley, Shana M. , Michele, Simona De , Santoriello, Dominick , Colby, Thomas V. , Bhagat, Govind , Bhagat, Govind , Saqi, Anjali

Mayo Clinic

American Journal of Surgical Pathology | September 30, 2020 | Volume: 45 | Issue: 3 | Pages: 405-413

10.1097/pas.0000000000001593 | PMID 33002919 Get It

Light chain deposition disease, characterized by nonamyloidogenic deposits of immunoglobulin light chains, is rare in the lung and possibly underdiagnosed due to low clinical suspicion and lack of readily accessible tests. We encountered a case of pulmonary light chain deposition disease (PLCDD) in which light chain deposits appeared crimson red with a Masson trichrome (MT) stain and salmon pink with a sulfated Alcian blue (SAB) stain. This prompted us to characterize a series of PLCDD cases and assess the utility of MT and SAB stains to distinguish them from amyloidosis. From the pathology archives of 2 institutions spanning 10 years, we identified 11 cases of PLCDD, including 7 diagnosed as such and 4 determined retrospectively. The deposits in all cases of PLCDD stained crimson red with MT and salmon pink with SAB, while the cases of pulmonary amyloid (n=10) stained blue-gray and blue-green, respectively. The immunoglobulin light chain nature of the deposits was confirmed in 10 of 11 cases by either immunofluorescence microscopy (n=5) or mass spectrometry (n=5). Transmission electron microscopy revealed osmiophilic, electron-dense deposits in all cases analyzed (n=3). An extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type was diagnosed in 10 cases and 1 represented a plasma cell neoplasm. Our study highlights the importance of considering PLCDD in the differential diagnosis of amyloid-like deposits in the lung and the value of performing MT and SAB stains to distinguish between PLCDD and amyloidosis.
Transbronchial Cryobiopsy in Interstitial Lung Diseases
Wells, Athol U. , Colby, Thomas V. , Maldonado, Fabien , Avasarala, Sameer K.

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | September 22, 2020 | Volume: 28 | Issue: 1 | Pages: 81-92

10.1097/lbr.0000000000000716 | PMID 32960830 Get It

Interstitial lung diseases are a heterogenous group of disorders that are often difficult to diagnose precisely. Clinical, laboratory, radiographic, and histologic information may be needed to arrive at the correct diagnosis. The multidisciplinary discussion has been proven to be useful in this patient group. Transbronchial cryobiopsy has become a popular method for obtaining tissue samples. Over the course of the last decade, there has been a significant amount of research assessing the feasibility, safety, and diagnostic endpoints of transbronchial cryobiopsy in patients with interstitial lung disease. Data continues to mount to support its use, which has been reflected in guidelines and expert panel reports. Patient selection, procedural performance, and appropriate specimen handling are critical factors for success. A coordinated approach by pulmonologists with expertise in interstitial lung diseases, interventional pulmonologists, and thoracic pathologists is essential. In this evidence-based narrative review, we address transbronchial cryobiopsies from these three distinct perspectives. In addition, the current literature was used to address nine common procedural questions.
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia
Scholand, Mary Beth , Lynch, David A. , Colby, Thomas V. , Groshong, Steve D. , Benzaquen, Sadia , Nathan, Steven D. , Davis, John R., Schmidt, Shelley L., Hagmeyer, Lars , Sonetti, David A., Hetzel, Jürgen, Case, Amy Hajari , Ramaswamy, Murali, Calero, Karel , Gauhar, Umair, Lancaster, Lisa , Choi, Yoonha, Pankratz, Daniel G., Walsh, P. Sean, Lofaro, Lori , Huang, Jing , Bhorade, Sangeeta , Kennedy, Giulia C., Raghu, Ganesh , Richeldi, Luca , Myers, Jeffrey L. , Chung, Jonathan Hero , Davis, J. Russell, Criner, Gerard J. , Patel, Nina , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 28, 2020 | Volume: 203 | Issue: 2 | Pages: 211-220

10.1164/rccm.202003-0877oc | PMID 32721166 Get It

Abstract Rationale Usual interstitial pneumonia (UIP) is the defining morphology of idiopathic pulmonary fibrosis (IPF). Guidelines for IPF diagnosis conditionally recommend surgical lung biopsy for histopathology diagnosis of UIP when radiology and clinical context are not definitive. A “molecular diagnosis of UIP” in transbronchial lung biopsy, the Envisia Genomic Classifier, accurately predicted histopathologic UIP. Objectives We evaluated the combined accuracy of the Envisia Genomic Classifier and local radiology in the detection of UIP pattern. Methods Ninety-six patients who had diagnostic lung pathology as well as a transbronchial lung biopsy for molecular testing with Envisia Genomic Classifier were included in this analysis. The classifier results were scored against reference pathology. UIP identified on high-resolution computed tomography (HRCT) as documented by features in local radiologists’ reports was compared with histopathology. Measurements and Main Results In 96 patients, the Envisia Classifier achieved a specificity of 92.1% (confidence interval [CI],78.6–98.3%) and a sensitivity of 60.3% (CI, 46.6–73.0%) for histology-proven UIP pattern. Local radiologists identified UIP in 18 of 53 patients with UIP histopathology, with a sensitivity of 34.0% (CI, 21.5–48.3%) and a specificity of 96.9% (CI, 83.8–100%). In conjunction with HRCT patterns of UIP, the Envisia Classifier results identified 24 additional patients with UIP (sensitivity 79.2%; specificity 90.6%). Conclusions In 96 patients with suspected interstitial lung disease, the Envisia Genomic Classifier identified UIP regardless of HRCT pattern. These results suggest that recognition of a UIP pattern by the Envisia Genomic Classifier combined with HRCT and clinical factors in a multidisciplinary discussion may assist clinicians in making an interstitial lung disease (especially IPF) diagnosis without the need for a surgical lung biopsy.
Mucinous Adenomyomatous Pulmonary Hamartoma: Clinicopathologic, Immunohistochemical, and Molecular Features of 6 Cases
Rossi, Giulio , Comin, Camilla, Jocollé, Genny, Jukna, Agita, Rotellini, Matteo, Colby, Thomas V. , Davoli, Fabio , Colby, Thomas

Mayo Clinic

International Journal of Surgical Pathology | July 27, 2020 | Volume: 29 | Issue: 3 | Pages: 273-280

10.1177/1066896920945016 | PMID 32715806 Get It

Pulmonary hamartoma (PH) may show various combinations of mesenchymal tissues with entrapment of respiratory epithelium. An uncommon variant of PH prevalently consisting of smooth muscle with mucinous proliferation has been reported in literature under several definitions as sporadic reports. We collected a series of 6 leiomyomatous PH associated with mucinous growth from consultation files (3 cases) and multicentric revision of archival files among 128 consecutive surgically resected PH. The lesions have a prevalence for male gender (5:1) and lower lobes (5:1), with a mean age at diagnosis of 61 years. All cases were incidentally disclosed in asymptomatic patients and had an indolent behavior. At histology, 2 cases consisted uniquely of smooth muscle and 4 also showed mature adipose tissue. The mucinous proliferation consisted of a monotonous growth of columnar cells lacking p63-positive basal cells and expressing pan-CKs, MUC5A, and CK7, but negative with TTF-1, napsin, MUC1, MUC2, MUC6, CK20, and CDX2. Smooth muscle was negative with hormonal receptors. Molecular analysis using a multiplex gene panel did not reveal gene mutations, while ALK, BRAF, and ROS1 were negative. In conclusion, we describe a small series of uncommon PH with prevalent leiomyomatous mesenchymal component associated with a mucinous growth (mucinous adenomyomatous hamartoma). Despite the lack of basal cells coating mucinous proliferation and irregular architecture, the favorable outcome and lack of molecular alterations most likely lay for a benign/low-grade tumor. Pathologists should be aware of this unusual occurrence to prevent a diagnosis of overt malignancy, particularly in frozen section, small biopsy, and cytology.
Evidence for Environmental–Human Microbiota Transfer at a Manufacturing Facility with Novel Work-related Respiratory Disease
Wu, Benjamin G. , Kapoor, Bianca , Cummings, Kristin J. , Stanton, Marcia, Nett, Randall J. , Kreiss, Kathleen, Abraham, Jerrold L. , Colby, Thomas V. , Franko, Angela, Green, Francis H. Y. , Sanyal, Soma, Clemente, José C. , Gao, Zhan , Coffre, Maryaline, Meyn, Peter, Heguy, Adriana , Borbet, Timothy C. , Koralov, Sergei B. , Tallaksen, Robert J. , Wendland, Douglas, Bachelder, Vance D., Boylstein, Randy, Cox‐Ganser, Jean M. , Virji, M. Abbas , Crawford, Judith A., Edwards, Nicole , Veillette, Marc , Warren, Krista, Lundeen, Sarah, Blaser, Martin J. , Segal, Leopoldo N. , Koralov, Sergei B , Blaser, Martin J , Segal, Leopoldo N , Li, Yonghua , Sulaiman, Imran , Park, Ju‐Hyeong , Duchaine, Caroline

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 16, 2020 | Volume: 202 | Issue: 12 | Pages: 1678-1688

10.1164/rccm.202001-0197oc | PMID 32673495 Get It

Abstract Rationale Workers’ exposure to metalworking fluid (MWF) has been associated with respiratory disease. Objectives As part of a public health investigation of a manufacturing facility, we performed a cross-sectional study using paired environmental and human sampling to evaluate the cross-pollination of microbes between the environment and the host and possible effects on lung pathology present among workers. Methods Workplace environmental microbiota were evaluated in air and MWF samples. Human microbiota were evaluated in lung tissue samples from workers with respiratory symptoms found to have lymphocytic bronchiolitis and alveolar ductitis with B-cell follicles and emphysema, in lung tissue samples from control subjects, and in skin, nasal, and oral samples from 302 workers from different areas of the facility. In vitro effects of MWF exposure on murine B cells were assessed. Measurements and Main Results An increased similarity of microbial composition was found between MWF samples and lung tissue samples of case workers compared with control subjects. Among workers in different locations within the facility, those that worked in the machine shop area had skin, nasal, and oral microbiota more closely related to the microbiota present in the MWF samples. Lung samples from four index cases and skin and nasal samples from workers in the machine shop area were enriched with Pseudomonas, the dominant taxa in MWF. Exposure to used MWF stimulated murine B-cell proliferation in vitro, a hallmark cell subtype found in the pathology of index cases. Conclusions Evaluation of a manufacturing facility with a cluster of workers with respiratory disease supports cross-pollination of microbes from MWF to humans and suggests the potential for exposure to these microbes to be a health hazard.